Metastatic spreading from solid tumors continues to be one of the greatest challenges facing oncologists and clinicians, often leading to a fatal outcome for many patients.
Immunotherapy is a diverse and broad catch-all for any treatments and therapies that utilize the patient’s own immune response to mount a defense.
Nexcelom founder and CTO, Dr. Jean Qiu, describes 3 major reasons why we partner with global and local research organizations to streamline CAR-T workflow.
Poster: High-throughput immune complex analysis method for CAR T cell-mediated cytotoxicity using the Celigo Image Cytometer
Download our Poster Abstract: Cancer immunotherapy has been gaining momentum in the field of cancer research. Specifically, Chimeric Antigen Receptor (CAR) T cell technology have introduced new methods to combat cancer. Direct cell-mediated cytotoxicity assays are required to assess the killing capability of the engineered CAR T cells. Traditionally, these assays are conducted by measuring the amount of released Chromium, calcein AM, or LDH molecules after the target cancer cells are killed with CAR T cells. These methods require a large amount of target cells which may not be ideal when working with donor primary samples. Additionally, they cannot [...]